Capmatinib (capmatinib)

Capmatinib is approved for: Adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test (full/regular FDA approval granted 10 Aug 2022). It is a capmatinib (Oral MET kinase inhibitor), originally marketed as Tabrecta (妥瑞达 in China) by Novartis (discovered by Incyte, licensed to Novartis in 2009).

Standard dosing for capmatinib: 400 mg orally twice daily with or without food. Tablets 150 mg and 200 mg; swallow whole, do not break, crush or chew. If a dose is missed or vomited, do not make up the dose, take the next dose at its scheduled time. Dose adjustments: Adverse-reaction dose reductions: first reduction 300 mg twice daily, second reduction 200 mg twice daily; permanently discontinue if 200 mg twice daily is not tolerated. ILD/pneumonitis of any grade: permanently discontinue. Grade 4 ALT/AST increase or ALT/AST >3x ULN with total bilirubin >2x ULN: permanently discontinue. Avoid concomitant strong and moderate CYP3A inducers.

Capmatinib is approved for: Adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test (full/regular FDA approval granted 10 Aug 2022). It is a capmatinib (Oral MET kinase inhibitor), originally marketed as Tabrecta (妥瑞达 in China) by Novartis (discovered by Incyte, licensed to Novartis in 2009).

The most frequently reported side effects of capmatinib are oedema (59%, grade 3-4 in 13%), nausea (46%), musculoskeletal pain (40%), fatigue (34%), vomiting (28%), dyspnoea (25%), cough (21%). Serious but less common reactions include interstitial lung disease / pneumonitis (4.8%, one fatal case in geometry mono-1), hepatotoxicity (increased alt/ast 15%), pancreatic toxicity (increased amylase/lipase 14%). Routine monitoring: Liver function tests (ALT, AST, total bilirubin) before starting, every 2 weeks for the first 3 months, then once a month or as clinically indicated; Amylase and lipase at baseline and regularly during treatment; Pulmonary symptoms for ILD/pneumonitis (dyspnoea, cough, fever). Report any new or worsening symptom to your treating physician — most adverse effects are managed by dose reduction rather than stopping treatment.

No FDA- or EMA-approved generic capmatinib (ANDA/abbreviated application) was identified. Lao copies such as LuciCapma are sold under Lao national registration and are not FDA/EMA-approved products. No published bioequivalence study against Tabrecta was found in this search. Tabrecta has FDA orphan-drug and breakthrough-therapy designations; US/EU compound and use patents remain in force, so copies circulate only in markets such as Laos and Bangladesh. Manufacturers supplying capmatinib generic versions include Laos Element Pharmaceutical, Lucius Pharmaceuticals. Brands registered in Bangladesh include Capmaxen.

Bangladesh benchmark: 1 manufacturers sell generic capmatinib 200 mg; unit prices range from BDT 1,500 (US$12.21) to BDT 1,500 (US$12.21), i.e. about US$366.24–US$366.24 per 30 units. Cheapest listed brand: Capmaxen (Everest Pharmaceuticals Ltd.) at BDT 1,500 per unit. Prices move with pack size, pharmacy and the exchange rate — confirm current stock and price with a licensed importer before ordering.

Capmatinib (Oral MET kinase inhibitor (small molecule), originally Tabrecta (妥瑞达 in China) by Novartis (discovered by Incyte, licensed to Novartis in 2009)) Capmatinib blocks the MET protein. In MET exon 14 skipping lung cancer the MET protein loses a regulatory part and signals constantly; capmatinib interrupts that signal, which slows or stops tumour growth. 400 mg orally twice daily with or without food. Tablets 150 mg and 200 mg; swallow whole, do not break, crush or chew. If a dose is missed or vomited, do not make up the dose, take the next dose at its scheduled time.

Storage: Dispense in the original package with the desiccant cartridge. Store at 20-25 C (68-77 F), excursions permitted between 15 and 30 C (59-86 F); protect from moisture. Discard unused tablets 6 weeks after first opening the bottle. Keep the product in its original packaging and check the expiry date printed on the pack.

Capmatinib (Oral MET kinase inhibitor (small molecule), originally Tabrecta (妥瑞达 in China) by Novartis (discovered by Incyte, licensed to Novartis in 2009)) Capmatinib blocks the MET protein. In MET exon 14 skipping lung cancer the MET protein loses a regulatory part and signals constantly; capmatinib interrupts that signal, which slows or stops tumour growth. 400 mg orally twice daily with or without food. Tablets 150 mg and 200 mg; swallow whole, do not break, crush or chew. If a dose is missed or vomited, do not make up the dose, take the next dose at its scheduled time.

Capmatinib (Oral MET kinase inhibitor (small molecule), originally Tabrecta (妥瑞达 in China) by Novartis (discovered by Incyte, licensed to Novartis in 2009)) Capmatinib blocks the MET protein. In MET exon 14 skipping lung cancer the MET protein loses a regulatory part and signals constantly; capmatinib interrupts that signal, which slows or stops tumour growth. 400 mg orally twice daily with or without food. Tablets 150 mg and 200 mg; swallow whole, do not break, crush or chew. If a dose is missed or vomited, do not make up the dose, take the next dose at its scheduled time.